Skip to main content

Table 4 Modelling the association of CSF biomarkers on AD biomarkers and clinical outcomes in ADNIa

From: Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders

 

All Participants

MCI

CN

Cross-sectional (MR)

β coefficient

P value

β coefficient

P value

β coefficient

P value

CSF t-tau

0.27

< 0.001

0.29

< 0.001

0.20

< 0.001

CSF p-tau

0.36

< 0.001

0.33

< 0.001

0.32

< 0.001

CSF Aβ42

−0.03

0.33

−0.04

0.32

0.006

0.86

CSF NFL

0.12

< 0.001

0.11

0.04

0.03

0.45

Plasma NFL

0.04

0.27

0.02

0.73

−0.04

0.53

Longitudinal (MELM)

 Hippocampus

−0.008

0.001

−0.007

0.04

−0.003

0.17

 Ventricles

0.006

0.13

0.005

0.36

0.003

0.43

Cox (Hazard ratio)

Statistic

P value

 

 MCI-to-AD dementia conversion

1.53 (1.15–2.0)

0.004

  1. Abbreviations: CN Cognitively normal, CSF Cerebrospinal fluid, MCI Mild cognitive impairment, p-tau Phosphorylated tau, t-tau Total tau, Cox Cox proportional hazards model, MELM Mixed effects linear model, MR Multiple regression
  2. aAll models were adjusted for age, gender, educational level, APOE ε4 genotype and intracranial volume (for MRI only). Models were tested in the whole cohort and in individual diagnostic groups